|

IDE161 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • IDEAYA Biosciences1

Indications

  • Solid Tumor Show to Express DLL31
  • Neuroendocrine Carcinomas1
  • Small Cell Lung Cancer1
  • Lung Cancer1
  • Cancer1

Denver, Colorado1 trial

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

Sarah Cannon Research Institute at HealthONE

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.